Japan Viral Vector And Plasmid Dna Manufacturing Market Size & Outlook
- Biotechnology
- Recombinant DNA & DNA Analysis
- Viral Vector And Plasmid DNA Manufacturing Market Outlook
- Recombinant DNA & DNA Analysis
Global Market
Related Markets
Ask Prism AI about the viral vector and plasmid dna manufacturing market
Get cited answers from GVR research on market growth, segments, regulations and forecasts.
- Source-linked answers
- Market-specific context
- Traceable figures
Japan viral vector and plasmid dna manufacturing market highlights
- The Japan viral vector and plasmid dna manufacturing market generated a revenue of USD 260.8 million in 2025 and is expected to reach USD 782.4 million by 2033.
- The Japan market is expected to grow at a CAGR of 14.8% from 2026 to 2033.
- In terms of segment, lentivirus was the largest revenue generating vector type in 2025.
- Adeno-associated virus (AAV) is the most lucrative vector type segment registering the fastest growth during the forecast period.
Viral vector and plasmid dna manufacturing market data book summary
| Market revenue in 2025 | USD 260.8 million |
| Market revenue in 2033 | USD 782.4 million |
| Growth rate | 14.8% (CAGR from 2026 to 2033) |
| Largest segment | Lentivirus |
| Fastest growing segment | Adeno-associated virus (AAV) |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Adeno-associated virus (AAV), Lentivirus, Adenovirus, Retrovirus, Plasmids |
| Key market players worldwide | Merck KGaA, Lonza Group Ltd, FUJIFILM Holdings Corp, Thermo Fisher Scientific Inc, Catalent Inc, WuXi Biologics (Cayman) Inc, Takara Bio Inc, Batavia Biosciences, Miltenyi Biotec, Revvity Inc, BioNTech SE ADR, Astellas Pharma Inc, Biomarin Pharmaceutical Inc, Regenxbio Inc |
Other key industry trends
- In terms of revenue, Japan accounted for 3.9% of the global viral vector and plasmid dna manufacturing market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, China viral vector and plasmid dna manufacturing market is projected to lead the regional market in terms of revenue in 2033.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,176.0 million by 2033.
Japan is anticipated to account for a significant share of the Asia Pacific viral vectors and plasmid DNA manufacturing market, as it has one of the most developed pharmaceutical and biotechnology sectors in the region.
Moreover, the high prevalence of chronic diseases and rare genetic disorders has led to increase in R&D activities for the development of novel therapies and vaccines, creating high demand for DNA manufacturing solutions for research purposes.
For instance, in May 2020, Takara Bio contracted AGC Biologics to produce an intermediate COVID-19 DNA vaccine (a circular DNA [pDNA] that includes the target pathogen's protein).
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
- Turnaround
- 5–10 working days
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Viral Vector And Plasmid DNA Manufacturing Market Scope
Viral Vector And Plasmid DNA Manufacturing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Takara Bio Inc | View profile | 1,793 | Nojihigashi 7-4-38 Kusatu, Shiga, Otsu, Japan, 520-0058 | www.takara-bio.co.jp |
| Revvity Inc | View profile | 11,500 | 940 Winter Street, Waltham, MA, United States, 02451 | www.revvity.com |
| WuXi Biologics (Cayman) Inc | View profile | 12,740 | No. 108, Meiliang Road, Mashan Binhu District, Wuxi, China, People's Republic of, 214092 | www.wuxibiologics.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Miltenyi Biotec | View profile | 1001-5000 | Bergisch Gladbach, Nordrhein-Westfalen, Germany, Europe | www.miltenyibiotec.com |
| Astellas Pharma Inc | View profile | 14,484 | 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, Japan, 103-8411 | www.astellas.com |
Japan Viral Vector And Plasmid DNA Manufacturing Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Viral Vector And Plasmid DNA Manufacturing Market Outlook will help companies and investors design strategic landscapes.
Lentivirus was the largest segment with a revenue share of 20.94% in 2025.
Horizon Databook has segmented the Japan viral vector and plasmid dna manufacturing market based on adeno-associated virus (aav), lentivirus, adenovirus, retrovirus, plasmids covering the revenue growth of each sub-segment from 2021 to 2033.
Japan is anticipated to account for a significant share of the Asia Pacific viral vectors and plasmid DNA manufacturing market, as it has one of the most developed pharmaceutical and biotechnology sectors in the region.
Moreover, the high prevalence of chronic diseases and rare genetic disorders has led to increase in R&D activities for the development of novel therapies and vaccines, creating high demand for DNA manufacturing solutions for research purposes.
For instance, in May 2020, Takara Bio contracted AGC Biologics to produce an intermediate COVID-19 DNA vaccine (a circular DNA [pDNA] that includes the target pathogen's protein).
- Japan Viral Vector And Plasmid Dna Manufacturing Market Vector Type Outlook (Revenue, USD Million , 2021-2033)
- Adeno-associated virus (AAV)
- Lentivirus
- Adenovirus
- Retrovirus
- Plasmids
- Others
- Japan Viral Vector And Plasmid Dna Manufacturing Market Workflow Outlook (Revenue, USD Million , 2021-2033)
- Upstream Processing
- Downstream Processing
- Japan Viral Vector And Plasmid Dna Manufacturing Market Application Outlook (Revenue, USD Million , 2021-2033)
- Antisense & RNAi
- Gene Therapy
- Cell Therapy
- Vaccinology
- Research Applications
- Japan Viral Vector And Plasmid Dna Manufacturing Market End-use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
- Japan Viral Vector And Plasmid Dna Manufacturing Market Disease Outlook (Revenue, USD Million , 2021-2033)
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Reasons to subscribe to Viral Vector And Plasmid DNA Manufacturing Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Viral Vector And Plasmid DNA Manufacturing Market Outlook databook
- Our clientele includes a mix of Viral Vector And Plasmid DNA Manufacturing Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Viral Vector And Plasmid DNA Manufacturing Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Viral Vector And Plasmid DNA Manufacturing Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Japan Viral Vector And Plasmid Dna Manufacturing Market, 2021-2033 (US$M)
Japan Vector Type - Viral Vector And Plasmid Dna Manufacturing Market Statistics, 2025 - 2033 (US$M)
